<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde &amp; Associates PC (the &#34;M&amp;A Class Action Firm&#34;), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating <ul type="disc"> <li> Cartica Acquisition Corp. (OTCMKTS: CRTAF) related to its merger with Nidar Infrastructure Ltd., in which the pre-transaction equity value of Nidar implied by the proposed transaction's terms is approximately $2.75 billion.</li> </ul> ACT NOW. The Shareholder Vote is scheduled for November 28, 2025. Click here for more information https://monteverdelaw.com/case/cartica-acquisition-corp/ . It is free and there is no cost or obligation to you. <ul type="disc"> <li> Akero Therapeutics, Inc. (NASDAQ: AKRO) related to its sale to Novo Nordisk A/S. Under the terms of the proposed transaction, Akero shareholders will receive $54.00 per share in cash, and a non-transferable contingent value right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin by June 30, 2031.</li> </ul> ACT NOW. The Shareholder Vote is scheduled for December 2, 2025. Click here for more information https://monteverdelaw.com/case/akero-therapeutics-inc/ https://monteverdelaw.com/case/premier-inc/ . It is free and there is no cost or obligation to you. <ul type="disc"> <li> Adverum Biotechnologies, Inc. (NASDAQ: NIC) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferable contingent value right (&#34;CVR&#34;) entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones.</li> </ul> ACT NOW. The Tender Offer expires on December 8, 2025. Click here for more information https://monteverdelaw.com/case/adverum-biotechnologies-inc/ . It is free and there is no cost or obligation to you. <ul type="disc"> <li> Barinthus Biotherapeutics plc (NASDAQ: BRNS) related to its merger with Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depository Share or ordinary share owned, and Clywedog shareholders will receive 4.358932 shares of common stock in the new combined company for each common or preferred share owned.</li> </ul> Click here for more info https://monteverdelaw.com/case/barinthus-biotherapeutics-plc/ . It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: <ol type="1"> <li>Do you file class actions and go to Court?</li> <li>When was the last time you recovered money for shareholders?</li> <li>What cases did you recover money in and how much?</li> </ol> About Monteverde &amp; Associates PC Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE &amp; ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 Attorney Advertising. (C) 2025 Monteverde &amp; Associates PC. The law firm responsible for this advertisement is Monteverde &amp; Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde &amp; Associates PC <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTEwJk5ld3NJdGVtSWQ9REMyMDM4NyZUcmFuc21pc3Npb25fSWQ9MjAyNTExMTAxNzMwUFJfTkVXU19VU1BSX19fX19EQzIwMzg3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTEwJk5ld3NJdGVtSWQ9REMyMDM4NyZUcmFuc21pc3Npb25fSWQ9MjAyNTExMTAxNzMwUFJfTkVXU19VU1BSX19fX19EQzIwMzg3"/></div> </div></div>

ADVM

BRNS

AKRO

CITE

Class Action Attorney Juan Monteverde of Monteverde & Associates PC is investigating mergers involving Cartica Acquisition Corp. (CRTAF), Akero Therapeutics (AKRO), Adverum Biotechnologies (NIC), and Barinthus Biotherapeutics (BRNS). Shareholder votes are scheduled for November 28, 2025, December 2, 2025, and December 8, 2025, respectively. The firm has a successful track record in recovering funds for shareholders and offers free consultations for those concerned about these transactions.

prnewswire

Adverum Biotech

Barinthus Biotherapeutics

Akero Therapeutics

Cartica Acquisition

17:30 ET
			
			
				$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS